{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:42:26Z","timestamp":1792384946899,"version":"4.4.0"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"33","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,11,19]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pioglitazone is mainly used for the management of type 2 diabetes and other insulinassociated\ndiseases. However, the molecular mechanism of pioglitazone can lead to an imbalance in bone metabolism,\nthus decreasing bone mass density (BMD) and increasing the risk for fractures.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To demonstrate the effect of pioglitazone therapy on bone metabolism and fat mass.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A comprehensive search of the PubMed, EMBASE, Web of Science and Cochrane Central databases\nfor randomized controlled trials (RCTs) on the effect of pioglitazone therapy on BMD and fat mass was performed.\nThe primary outcome measures were the measured values of BMD, percentage changes in BMD, measured\nvalues of bone turnover markers and bone metabolic hormones, changes in BMI, body and leg fat mass, and\nfracture rates. The final search was performed in May 2019.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Six RCTs were included. A total of 749 patients met the inclusion criteria. Pioglitazone therapy was\nshown to significantly reduce the BMD of the whole body, lumbar spine, and total hip and serum PTH levels and\nincrease BMI, total body fat mass and leg fat mass. In addition, 30 mg\/d and 30 mg\/d initially for one month\nfollowed by 45 mg\/d pioglitazone could reduce the BMD of the lumbar spine. Pioglitazone therapy exerted no\nsignificant influence on the BMD of the femoral neck, serum BSAP or 25-OHD levels, or fracture rates.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Compared with placebo, pioglitazone therapy reduced BMD and serum PTH levels and increased fat\nmass and BMI with no difference in serum BSAP or 25-OHD levels or fracture rates; 30 mg\/d pioglitazone was\nsufficient to reduce the BMD of the lumbar spine.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190920123129","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T09:38:34Z","timestamp":1568972314000},"page":"3590-3596","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pioglitazone Therapy Decreases Bone Mass Density and Increases Fat Mass: A Meta-Analysis"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1740-7758","authenticated-orcid":true,"given":"Liyun","family":"Zuo","sequence":"first","affiliation":[{"name":"Medical College of Shanxi Datong University, Shanxi, 037009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4190-8368","authenticated-orcid":true,"given":"Jianbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical College of Shanxi Datong University, Shanxi, 037009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-2451","authenticated-orcid":true,"given":"Nianping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical College of Shanxi Datong University, Shanxi, 037009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4864-6559","authenticated-orcid":true,"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Changzhi Medical College, Changzhi, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"Yki-J\u00e4rvinen H.","year":"2004","unstructured":"Yki-J\u00e4rvinen H.; Thiazolidinediones N Engl J Med 2004,351(11),1106-1118","journal-title":"N Engl J Med"},{"key":"ref=2","author":"Lord J.M.","year":"2003","unstructured":"Lord J.M.; Flight I.H.; Norman R.J.; Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003(3)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","volume":"368","author":"Gerstein H.C.","year":"2006","unstructured":"Gerstein H.C.; Yusuf S.; Bosch J.; Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006,368(9541),1096-1105","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"Liao H.W.","year":"2017","unstructured":"Liao H.W.; Saver J.L.; Wu Y.L.; Chen T.H.; Lee M.; Ovbiagele B.; Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017,7(1)","journal-title":"BMJ Open"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1172\/JCI10843","volume":"106","author":"Olefsky J.M.","year":"2000","unstructured":"Olefsky J.M.; Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000,106(4),467-472","journal-title":"J Clin Invest"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","volume":"116","author":"McGavock J.M.","year":"2007","unstructured":"McGavock J.M.; Lingvay I.; Zib I.; Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation 2007,116(10),1170-1175","journal-title":"Circulation"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/sj.ijo.0802625","volume":"28","author":"Bajaj M.","year":"2004","unstructured":"Bajaj M.; Suraamornkul S.; Hardies L.J.; Pratipanawatr T.; DeFronzo R.A.; Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004,28(6),783-789","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/ncpendmet0920","volume":"4","author":"McDonough A.K.","year":"2008","unstructured":"McDonough A.K.; Rosenthal R.S.; Cao X.; Saag K.G.; The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab 2008,4(9),507-513","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11596-012-0091-x","volume":"32","author":"Wang L.","year":"2012","unstructured":"Wang L.; Li L.; Gao H.; Li Y.; Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes. J Huazhong Univ Sci Technolog Med Sci 2012,32(4),530-533","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1463-1326.2008.00931.x","volume":"11","author":"Grey A.","year":"2009","unstructured":"Grey A.; Thiazolidinedione-induced skeletal fragility-mechanisms and implications. Diabetes Obes Metab 2009,11(4),275-284","journal-title":"Diabetes Obes Metab"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000154","volume":"6","author":"Douglas I.J.","year":"2009","unstructured":"Douglas I.J.; Evans S.J.; Pocock S.; Smeeth L.; The risk of fractures associated with thiazolidinediones: A self-controlled case-series study. PLoS Med 2009,6(9)","journal-title":"PLoS Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2174\/1871530318666180423121833","volume":"18","author":"Pavlova V.","year":"2018","unstructured":"Pavlova V.; Filipova E.; Uzunova K.; Kalinov K.; Vekov T.; Pioglitazone therapy and fractures: Systematic review and meta- analysis. Endocr Metab Immune Disord Drug Targets 2018,18(5),502-507","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1210\/jc.2007-2249","volume":"93","author":"Glintborg D.","year":"2008","unstructured":"Glintborg D.; Andersen M.; Hagen C.; Heickendorff L.; Hermann A.P.; Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008,93(5),1696-1701","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s00198-017-4164-3","volume":"28","author":"Pop L.M.","year":"2017","unstructured":"Pop L.M.; Lingvay I.; Yuan Q.; Li X.; Adams-Huet B.; Maalouf N.M.; Impact of pioglitazone on bone mineral density and bone marrow fat content. Osteoporos Int 2017,28(11),3261-3269","journal-title":"Osteoporos Int"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","volume":"58","author":"Billington E.O.","year":"2015","unstructured":"Billington E.O.; Grey A.; Bolland M.J.; The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 2015,58(10),2238-2246","journal-title":"Diabetologia"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.bbrc.2007.10.057","volume":"364","author":"Sears D.D.","year":"2007","unstructured":"Sears D.D.; Hsiao A.; Ofrecio J.M.; Chapman J.; He W.; Olefsky J.M.; Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem Biophys Res Commun 2007,364(3),515-521","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/dmrr.1187","volume":"27","author":"Henriksen K.","year":"2011","unstructured":"Henriksen K.; Byrjalsen I.; Qvist P.; Efficacy and safety of the PPAR\u03b3 partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011,27(4),392-401","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1210\/jc.2012-4096","volume":"98","author":"Bone H.G.","year":"2013","unstructured":"Bone H.G.; Lindsay R.; McClung M.R.; Perez A.T.; Raanan M.G.; Spanheimer R.G.; Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013,98(12),4691-4701","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/dom.12099","volume":"15","author":"Bray G.A.","year":"2013","unstructured":"Bray G.A.; Smith S.R.; Banerji M.A.; Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab 2013,15(10),931-937","journal-title":"Diabetes Obes Metab"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1530\/EJE-11-1075","volume":"166","author":"Grey A.","year":"2012","unstructured":"Grey A.; Beckley V.; Doyle A.; Pioglitazone increases bone marrow fat in type 2 diabetes: Results from a randomized controlled trial. Eur J Endocrinol 2012,166(6),1087-1091","journal-title":"Eur J Endocrinol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejrad.2009.04.074","volume":"71","author":"Adams J.E.","year":"2009","unstructured":"Adams J.E.; Quantitative computed tomography. Eur J Radiol 2009,71(3),415-424","journal-title":"Eur J Radiol"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004947","volume":"95","author":"He L.","year":"2016","unstructured":"He L.; Liu X.; Wang L.; Yang Z.; Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016,95(42)","journal-title":"Medicine (Baltimore)"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T10:25:05Z","timestamp":1576578305000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175029\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":22,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,11,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190920123129","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}